Pharmaceutical giants like Eli Lilly, Pfizer, and Merck are increasing their manufacturing investments in the United States as they navigate the shifting landscape of trade tariffs and take advantage of domestic tax incentives.
According to GlobalData, this strategic pivot is aimed at strengthening supply chain resilience, but it may also lead to higher production costs and increased drug prices, sparking concerns about healthcare affordability, particularly in emerging markets.
Eli Lilly, for instance, has committed to investing at least $27 billion in four new US manufacturing sites, with a focus on active pharmaceutical ingredients (APIs) and injectables. Pfizer is also considering relocating some of its overseas production to US facilities, contingent on the evolving tariff situation.
Meanwhile, Merck has recently opened a $1 billion facility in North Carolina to ramp up production of its HPV vaccine, Gardasil. These investments are fueled, in part, by the tax cuts from President Trump’s first term, which have been deemed instrumental by Lilly’s CEO in supporting domestic manufacturing.
However, this push for increased US production is not without its challenges. As companies scale up manufacturing domestically, the potential for higher production costs could translate into higher drug prices, exacerbating concerns around access to healthcare, especially in the face of rising inflation and unemployment in the US.
On the global stage, BRICS nations—Brazil, Russia, India, China, and South Africa—are driving regulatory reforms aimed at improving access to affordable medicines, particularly biosimilars and biologics. These efforts focus on regulatory harmonization to eliminate barriers to these vital drugs, potentially offsetting the inflationary pressures from US tariffs. This shift positions BRICS countries as emerging leaders in global pharmaceutical manufacturing, fostering competition, reducing costs, and enhancing access to essential medicines.
